Chu QS - Search Results

1

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.

Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS. Rottey S, et al. Among authors: chu qs. Clin Cancer Res. 2022 Jan 1;28(1):95-105. doi: 10.1158/1078-0432.CCR-21-1181. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615718 Free PMC article. Clinical Trial.

2

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK. Chu QS, et al. Clin Cancer Res. 2004 Aug 1;10(15):4913-21. doi: 10.1158/1078-0432.CCR-04-0469. Clin Cancer Res. 2004. PMID: 15297391 Clinical Trial.

3

A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.

Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B, Gyorffy S, Munzert G. Ellis PM, et al. Among authors: chu qs. Clin Lung Cancer. 2013 Jan;14(1):19-27. doi: 10.1016/j.cllc.2012.04.003. Epub 2012 Jun 1. Clin Lung Cancer. 2013. PMID: 22658814 Clinical Trial.

4

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW. Chu QS, et al. Invest New Drugs. 2014 Dec;32(6):1226-35. doi: 10.1007/s10637-014-0139-9. Epub 2014 Jul 19. Invest New Drugs. 2014. PMID: 25037863 Clinical Trial.

5

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.

Chu QS, Sangha R, Spratlin J, Vos LJ, Mackey JR, McEwan AJ, Venner P, Michelakis ED. Chu QS, et al. Invest New Drugs. 2015 Jun;33(3):603-10. doi: 10.1007/s10637-015-0221-y. Epub 2015 Mar 13. Invest New Drugs. 2015. PMID: 25762000 Clinical Trial.

6

Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors.

Chu QS, Bouganim N, Fortier C, Zaknoen S, Stille JR, Kremer JD, Yuen E, Hui YH, de la Peña A, Lithio A, Smith PS, Batist G. Chu QS, et al. Invest New Drugs. 2021 Aug;39(4):1001-1010. doi: 10.1007/s10637-020-01049-3. Epub 2021 Jan 22. Invest New Drugs. 2021. PMID: 33479856 Clinical Trial.

7

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.

Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N. Chu Q, et al. JTO Clin Res Rep. 2022 Aug 27;3(11):100400. doi: 10.1016/j.jtocrr.2022.100400. eCollection 2022 Nov. JTO Clin Res Rep. 2022. PMID: 36275912 Free PMC article.

8

Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates.

Chu Q. Chu Q. Curr Oncol Rep. 2023 Apr;25(4):309-323. doi: 10.1007/s11912-023-01367-8. Epub 2023 Feb 10. Curr Oncol Rep. 2023. PMID: 36763234 Review.

9

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).

Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, Spreafico A, Lewis KD, Bruno DS, Dumas O, McDermott DF, Strauss JF, Chu QS, Gilbert L, Chaudhry A, Calvo E, Dalal R, Boni V, Ernstoff MS, Velcheti V. Vaishampayan UN, et al. Among authors: chu qs. J Immunother Cancer. 2024 Nov 20;12(11):e010143. doi: 10.1136/jitc-2024-010143. J Immunother Cancer. 2024. PMID: 39567211 Free PMC article. Clinical Trial.

10

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Luke JJ, et al. Among authors: chu qs. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0439. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670852

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters